Trimetazidine use and the risk of parkinsonism: A nationwide population-based study
- Authors
- Kim, Seungyeon; Yu, Yun Mi; Kwon, Jeongyoon; Jeong, Kyeong Hye; Lee, Jeong Sang; Lee, Euni
- Issue Date
- Oct-2020
- Publisher
- MDPI AG
- Keywords
- Drug-induced parkinsonism; Parkinsonism; Trimetazidine
- Citation
- International Journal of Environmental Research and Public Health, v.17, no.19, pp 1 - 11
- Pages
- 11
- Journal Title
- International Journal of Environmental Research and Public Health
- Volume
- 17
- Number
- 19
- Start Page
- 1
- End Page
- 11
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/52063
- DOI
- 10.3390/ijerph17197256
- ISSN
- 1661-7827
1660-4601
- Abstract
- An association between trimetazidine (TMZ), an anti-anginal drug, and parkinsonism has been reported in a number of studies. However, evidence from studies with long-term follow-up and better validity is lacking. We investigated the risk of TMZ-associated parkinsonism, specifically the incidence rate, cumulative dose–response relationship, and combined effects with other parkinsonism-inducing medications. This propensity score-matched retrospective cohort study was conducted using 14-year health insurance claims data in South Korea. The risk of parkinsonism was evaluated using multivariate Cox proportional hazard regression analysis, adjusted for comorbidities and concurrent medications. A total of 9712 TMZ users and 29,116 matched non-TMZ users were included. TMZ users had a significantly higher incidence rate of parkinsonism than non-TMZ users (9.34 vs. 6.71 per 1000 person-years; p < 0.0001). TMZ use significantly increased the risk of parkinsonism (adjusted hazard ratio = 1.38; 95% confidence interval = 1.26–1.51). Increased risks were observed with accumulated doses of TMZ, as well as concurrent use of other parkinsonism-inducing medications. The findings indicate that TMZ use significantly increases the risk of parkinsonism in the South Korean population. Closer monitoring should be considered for TMZ users, especially for those who are older, using TMZ at high cumulative doses and other parkinsonism-inducing medications. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/52063)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.